OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario
Carolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5512-5512
Open Access | Times Cited: 18
Carolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5512-5512
Open Access | Times Cited: 18
Showing 18 citing articles:
Clinical manifestations and risk factors for COVID-19 and its severity in patients with hematological malignancies
Tzong‐Yow Wu, Wan-Ting Tsai, Kai-Hsiang Chen, et al.
Journal of Microbiology Immunology and Infection (2024) Vol. 57, Iss. 3, pp. 403-413
Open Access | Times Cited: 2
Tzong‐Yow Wu, Wan-Ting Tsai, Kai-Hsiang Chen, et al.
Journal of Microbiology Immunology and Infection (2024) Vol. 57, Iss. 3, pp. 403-413
Open Access | Times Cited: 2
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes
Wenjing Guo, Yizhou Zheng, Sizhou Feng
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Wenjing Guo, Yizhou Zheng, Sizhou Feng
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination—A Retrospective Cohort Study
Stella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 524-524
Open Access | Times Cited: 3
Stella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 524-524
Open Access | Times Cited: 3
Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients
Elisabetta Schiaroli, Anna Gidari, Giovanni Brachelente, et al.
Journal of Clinical Virology (2023) Vol. 168, pp. 105584-105584
Open Access | Times Cited: 3
Elisabetta Schiaroli, Anna Gidari, Giovanni Brachelente, et al.
Journal of Clinical Virology (2023) Vol. 168, pp. 105584-105584
Open Access | Times Cited: 3
Inactivated Vaccine Dosage and Serum IgG Levels Correlate with Persistent COVID-19 Infection in Hematologic Malignancy Patients During the Omicron Surge in China
Ye Li, Ye Yang, Xuewu Zhang, et al.
Research Square (Research Square) (2024)
Open Access
Ye Li, Ye Yang, Xuewu Zhang, et al.
Research Square (Research Square) (2024)
Open Access
Inactivated vaccine dosage and serum IgG levels correlate with persistent COVID-19 infections in hematologic malignancy patients during the Omicron Surge in China
Ye Li, Ye Yang, Xuewu Zhang, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Ye Li, Ye Yang, Xuewu Zhang, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
11-month SARS-CoV-2 immunogenicity decay, and associated factors, among mRNA vaccinees: Implications for Booster Vaccination
Michael Asamoah-Boaheng, Brian Grunau, Scott Haig, et al.
(2023)
Open Access
Michael Asamoah-Boaheng, Brian Grunau, Scott Haig, et al.
(2023)
Open Access
Benefit of repeatedCOVID ‐19 vaccination for patients with B‐cell malignancies
Ulrike Bacher, Evgenii Shumilov, Thomas Pabst
British Journal of Haematology (2023) Vol. 202, Iss. 6, pp. 1081-1083
Open Access
Ulrike Bacher, Evgenii Shumilov, Thomas Pabst
British Journal of Haematology (2023) Vol. 202, Iss. 6, pp. 1081-1083
Open Access
11-month SARS-CoV-2 immunogenicity decay, and associated factors, among mRNA vaccinees: Implications for Booster Vaccination
Michael Asamoah-Boaheng, Brian Grunau, Scott Haig, et al.
(2023)
Open Access
Michael Asamoah-Boaheng, Brian Grunau, Scott Haig, et al.
(2023)
Open Access
Increasing insight in the value of repetitive COVID ‐19 vaccination in patients with haematological malignancies in the Omicron era
Ulrike Bacher, Evgenii Shumilov, Thomas Pabst
British Journal of Haematology (2023) Vol. 204, Iss. 2, pp. 386-388
Open Access
Ulrike Bacher, Evgenii Shumilov, Thomas Pabst
British Journal of Haematology (2023) Vol. 204, Iss. 2, pp. 386-388
Open Access
Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies
Line Dam Heftdal, Cecilie Bo Hansen, Sebastian Rask Hamm, et al.
Viruses (2023) Vol. 16, Iss. 1, pp. 11-11
Open Access
Line Dam Heftdal, Cecilie Bo Hansen, Sebastian Rask Hamm, et al.
Viruses (2023) Vol. 16, Iss. 1, pp. 11-11
Open Access
